Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KEPPRA XR vs DIPHENYLAN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Adjunctive therapy for partial-onset seizures in adults and children aged ≥4 years,Adjunctive therapy for myoclonic seizures in adults and adolescents aged ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children aged ≥6 years with idiopathic generalized epilepsy
FDA-approved: Generalized tonic-clonic seizures, complex partial seizures,Off-label: Prevention of seizures during neurosurgery, status epilepticus (parenteral), trigeminal neuralgia
1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.
100 mg orally every 8 hours
7.1 ± 1.1 hours in adults; 10–11 hours in elderly; prolonged in renal impairment (up to 25 hours in severe renal failure).
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Metabolized primarily by hydrolysis of the acetamide group via enzymatic hydrolysis (not CYP450 dependent); forms inactive metabolite (UCB L057); ~24% of dose undergoes oxidative metabolism.
Primarily hepatic metabolism via CYP2C9 and CYP2C19 isoenzymes, with saturation kinetics at therapeutic concentrations. Major metabolite: 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH).
Renal: 66% as unchanged drug; 27% as inactive metabolite (uch L057); biliary/fecal: negligible (<1%).
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
<10%; binding to albumin (not extensive).
90-95% mainly to albumin; displaces and is displaced by other highly protein-bound drugs.
0.5–0.7 L/kg; suggests distribution into total body water.
0.6-0.8 L/kg; larger in neonates (up to 1.2 L/kg); indicates extensive tissue binding, particularly in brain and adipose.
100% for oral tablet (immediate-release); 100% for extended-release (relative to immediate-release).
Oral: 85-95% (capsules and tablets); intramuscular: 70-80% due to precipitation at injection site.
For Cr Cl > 80 m L/min: 1500 mg once daily; Cr Cl 50-80 m L/min: 1000 mg once daily; Cr Cl 30-49 m L/min: 500 mg once daily; Cr Cl < 30 m L/min: 250 mg once daily. ESRD on dialysis: 500 mg once daily with 250 mg supplemental dose post-dialysis.
No adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, administer every 12-24 hours; for GFR <10 m L/min, administer every 24 hours with monitoring of serum levels
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), reduce dose by 50%.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or reduce dose by 50-75% with close monitoring
For children ≥12 years (≥40 kg): 1500 mg orally once daily. Not FDA-approved for <12 years; use immediate-release formulation for pediatric patients <12 years: starting dose 10 mg/kg twice daily, titrated to 30 mg/kg twice daily.
5-7 mg/kg/day orally divided every 8-12 hours, not to exceed 300 mg/day
Elderly patients often have reduced creatinine clearance; dose should be adjusted based on renal function. Monitor for drowsiness, dizziness, and ataxia. Start at lower end of dosing range and titrate cautiously.
Initial dose of 50 mg orally every 8 hours, titrate slowly based on response and tolerability; monitor renal function and serum levels
No FDA black box warning.
Intravenous administration: Risk of serious cardiovascular reactions including hypotension and cardiac arrest, especially in elderly patients and those with underlying cardiac disease. Rate of infusion should not exceed 50 mg/min in adults.
Behavioral abnormalities including psychosis, aggression, hostility, irritability, and suicidal ideation/behavior,Somnolence and fatigue,Serious dermatologic reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (decreased red blood cell, white blood cell, and platelet counts),Increased blood pressure in pediatric patients,Withdrawal seizures upon abrupt discontinuation
1. Cardiovascular risk with IV administration. 2. Suicide risk and behavioral changes. 3. Hepatotoxicity (monitor LFTs). 4. Hematologic effects (agranulocytosis, thrombocytopenia). 5. Lymphadenopathy. 6. Teratogenicity (fetal hydantoin syndrome). 7. Hyperglycemia. 8. Withdrawal seizures. 9. Dermatologic reactions (Stevens-Johnson syndrome). 10. Osteoporosis with chronic use.
Hypersensitivity to levetiracetam or any component of the formulation
Absolute: Hypersensitivity to phenytoin, hydantoins, or any component; sinus bradycardia, sinoatrial block, second- or third-degree AV block, or Stokes-Adams syndrome (IV formulation); concurrent use with delavirdine. Relative: Pregnancy (especially first trimester; weigh risk vs benefit), hepatic impairment, alcoholism, porphyria.
No significant food interactions. Grapefruit juice does not affect levetiracetam. Avoid alcohol as it may exacerbate CNS depression.
Avoid grapefruit and grapefruit juice as it inhibits CYP metabolism and can increase phenytoin levels. Enteral feeding formulas may reduce absorption; administer phenytoin 1-2 hours before or after enteral feeds. High doses of folic acid may decrease phenytoin levels. Chronic use can lead to vitamin D and folate deficiency; consider supplementation if indicated. Alcohol consumption should be minimized—acute intake can increase levels while chronic use decreases them.
Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy association unclear but may be dose-dependent. Second/third trimester: Risk of fetal growth restriction, hemorrhagic disease of newborn (vitamin K deficiency due to enzyme induction). Perinatal: Neonatal withdrawal syndrome, sedation, and coagulopathy.
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of bleeding disorders in the newborn due to vitamin K deficiency, and potential for neonatal withdrawal and growth restriction.
Levetiracetam is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is low (2–7% of weight-adjusted maternal dose). Limited data suggest no adverse effects in breastfed infants, but monitor for drowsiness, poor feeding. Benefit likely outweighs risk in most cases.
Diphenhydramine is excreted into breast milk in small amounts; reported M/P ratio is approximately 0.5 to 1.0. In infants, risks of drowsiness, irritability, and paradoxical excitation. Generally considered compatible with breastfeeding, but monitor infant for adverse effects.
Increased clearance of levetiracetam during pregnancy, particularly in the second and third trimesters (up to 50–60% higher). Dose adjustments may be required to maintain therapeutic trough levels (target 12–46 µg/m L). Consider therapeutic drug monitoring every 1–3 months and after delivery, with gradual dose reduction to pre-pregnancy levels within 1–2 weeks postpartum.
No specific dose adjustments are typically required. However, due to increased volume of distribution and metabolism in pregnancy, therapeutic levels may need monitoring. Initial dose adjustments are not recommended, but consider dose increases if clinical response is inadequate.
Keppra XR (levetiracetam extended-release) is dosed once daily due to its prolonged absorption profile. Therapeutic drug monitoring is not routinely required because of its predictable pharmacokinetics and wide therapeutic index. Adjust dose in renal impairment (Cr Cl < 80 m L/min) using ideal body weight; supplement dose after hemodialysis. May cause somnolence, dizziness, and behavioral changes (e.g., aggression, psychosis) especially in pediatric and elderly patients. Stevens-Johnson syndrome and angioedema are rare but serious adverse effects. Sudden discontinuation may precipitate withdrawal seizures; taper over at least 2 weeks.
Diphenylan Sodium (phenytoin sodium) is a hydantoin anticonvulsant used for generalized tonic-clonic and complex partial seizures. It exhibits zero-order kinetics at therapeutic levels; small dose increases can cause disproportionate toxicity. Monitor for nystagmus, ataxia, and mental status changes as early signs of toxicity. Due to high protein binding (90%), hypoalbuminemia or uremia increases free fraction—adjust doses based on free phenytoin levels. Can cause folate deficiency, megaloblastic anemia, and bone density loss. Gingival hyperplasia occurs in 40% of patients; meticulous oral hygiene can reduce severity. Dosing must be individualized with therapeutic range 10-20 mg/L total (1-2 mg/L free). Intravenous loading requires cardiac monitoring due to risk of bradycardia and hypotension; avoid IM use due to crystallization and erratic absorption.
Take exactly as prescribed once daily with or without food, at the same time each day.,Swallow tablet whole; do not crush, chew, or break.,Do not drive or operate heavy machinery until you know how this medicine affects you.,Contact your doctor immediately if you experience skin rash, blistering, swelling of face/lips, or difficulty breathing.,Inform your doctor of any history of depression, mood swings, aggressive behavior, or suicidal thoughts.,Report any worsening of seizures or new types of seizures.,If you are on dialysis, take the recommended supplement dose after each session.,Do not stop taking this medicine suddenly as it may cause withdrawal seizures.,Avoid alcohol while taking Keppra XR; it may increase drowsiness and dizziness.
Take exactly as prescribed; do not stop abruptly as withdrawal can trigger seizures.,Avoid alcohol and grapefruit juice; they can affect drug levels and increase side effects.,Practice good oral hygiene with regular brushing and flossing to prevent gum overgrowth.,Report any rash, fever, sore throat, or easy bruising immediately—these may signal serious blood disorders.,Use non-hormonal contraception if on birth control; phenytoin reduces efficacy of oral contraceptives.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Wear a medical alert bracelet if you have epilepsy.,Do not take antacids within 2 hours of phenytoin.,Regular blood tests are needed to monitor drug levels and liver function.,If you become pregnant, discuss with your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KEPPRA XR vs DIPHENYLAN SODIUM, answered by our medical review team.
KEPPRA XR is a Antiepileptic that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal excitability.. DIPHENYLAN SODIUM is a Antiepileptic that works by Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KEPPRA XR and DIPHENYLAN SODIUM depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KEPPRA XR is: 1500 mg orally once daily (2 tablets of 750 mg). Extended-release formulation is taken once daily; immediate-release is dosed twice daily.. The standard adult dose of DIPHENYLAN SODIUM is: 100 mg orally every 8 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KEPPRA XR and DIPHENYLAN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KEPPRA XR is classified as Category C. Pregnancy Category C. First trimester: Increased risk of major congenital malformations (e.g., neural tube defects, cleft palate) with antiepileptic drug polytherapy; monotherapy a. DIPHENYLAN SODIUM is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of b. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.